The experimental data collected over
the past 15 years on the interaction
of decavanadate(V) (V
10
O
28
6–
; V
10
), a polyoxometalate (POM) with promising anticancer
and antibacterial action, with G-actin, were rationalized by using
several computational approaches (docking, density functional theory
(DFT), and molecular dynamics (MD)). Moreover, a comparison with the
isostructural and more stable decaniobate(V) (Nb
10
O
28
6–
; Nb
10
) was carried out. Four
binding sites were identified, named α, β, γ, and
δ, the site α being the catalytic nucleotide site located
in the cleft of the enzyme at the interface of the subdomains II and
IV. It was observed that the site α is preferred by V
10
, whereas Nb
10
is more stable at the site β; this
indicates that, differently from other proteins, G-actin could contemporaneously
bind the two POMs, whose action would be synergistic. Both decavanadate
and decaniobate induce conformational rearrangements in G-actin, larger
for V
10
than Nb
10
. Moreover, the binding mode
of oxidovanadium(IV) ion, V
IV
O
2+
, formed upon
the reduction of decavanadate(V) by the –SH groups of accessible
cysteine residues, is also found in the catalytic site α with
(His161, Asp154) coordination; this adduct overlaps significantly
with the region where ATP is bound, accounting for the competition
between V
10
and its reduction product V
IV
O
2+
with ATP, as previously observed by EPR spectroscopy. Finally,
the competition with ATP was rationalized: since decavanadate prefers
the nucleotide site α, Ca
2+
-ATP displaces V
10
from this site, while the competition is less important
for Nb
10
because this POM shows a higher affinity
for β than for site α. A relevant consequence of this paper is that other metallodrug–protein
systems, in the absence or presence of eventual inhibitors and/or
competition with molecules of the organism,
could be studied with the same approach,
suggesting important elements for an explanation
of the biological data and a rational drug design.